BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 29058836)

  • 1. [The major SCAR syndromes].
    Piérard GE; Lesuisse M; Piérard-Franchimont C
    Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments for Severe Cutaneous Adverse Reactions.
    Cho YT; Chu CY
    J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug reaction with eosinophilia and systemic symptoms].
    Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
    Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS Syndromes - A Narrative Review.
    Pakkir Maideen NM; Barakat IR; Jumale AH
    Curr Drug Saf; 2024; 19(2):218-223. PubMed ID: 37151075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
    Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
    Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
    Owen CE; Jones JM
    Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Harr T; French LE
    Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse cutaneous drug eruptions: current understanding.
    Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
    Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
    Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
    Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?
    Horcajada-Reales C; Pulido-Pérez A; Suárez-Fernández R
    Actas Dermosifiliogr; 2016; 107(1):23-33. PubMed ID: 26520037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
    van Hattem S; Beerthuizen GI; Kardaun SH
    Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient management and follow-up recommendations for adverse drug reactions: guidelines for posthospitalization care.
    Khanna R; Vaudreuil A; Lake E
    Cutis; 2019 May; 103(5):254-256;258. PubMed ID: 31233575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute generalized exanthematous pustulosis with blistering mimicking toxic epidermal necrolysis, associated with a primary mumps infection.
    Azib S; Florin V; Fourrier F; Delaporte E; Staumont-Sallé D
    Clin Exp Dermatol; 2014 Aug; 39(6):723-5. PubMed ID: 24986490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.
    Darlenski R; Kazandjieva J; Tsankov N
    Clin Dermatol; 2015; 33(5):538-41. PubMed ID: 26321400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
    Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
    Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe cutaneous adverse reactions to drugs.
    Duong TA; Valeyrie-Allanore L; Wolkenstein P; Chosidow O
    Lancet; 2017 Oct; 390(10106):1996-2011. PubMed ID: 28476287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
    Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
    J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature.
    Peermohamed S; Haber RM
    Arch Dermatol; 2011 Jun; 147(6):697-701. PubMed ID: 21690532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.
    Barbaud A; Castagna J; Soria A
    Contact Dermatitis; 2022 May; 86(5):344-356. PubMed ID: 35122269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
    Hadavand MA; Kaffenberger B; Cartron AM; Trinidad JCL
    J Am Acad Dermatol; 2022 Sep; 87(3):632-639. PubMed ID: 32926975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.